Isoquinoline Piperazine Compounds for Selective NET Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NET inhibitor drugs often have non-selective binding profiles, interacting with other CNS proteins like SERT and DAT, limiting their effectiveness as therapeutics for NE-based psychiatric disorders, and there is a need for more selective and potent imaging tracers for NET in diagnosing CNS diseases.
Innovation Solution
Development of structurally novel 1-[(2′-substituted)-piperazin-1′-yl]-isoquinoline compounds with high selectivity for the norepinephrine transporter (NET) protein, which can be used as potent pharmacological agents and radioactive tracers for imaging NET densities in tissues using PET and SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NET inhibitor drugs are used, then they can block norepinephrine reuptake and enhance synaptic concentrations, but they exhibit non-selective binding profiles interacting with other CNS proteins like SERT and DAT
Solution Approach 1:
The patent modifies specific regions of the isoquinoline molecule by substituting at the 2' position of the piperazine ring with particular groups (such as fluorine, methyl, or hydroxyl groups) to enhance selectivity for NET while reducing interactions with SERT and DAT. This local structural modification optimizes the binding characteristics at the target site without affecting other CNS transporters
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types, positions, and stereochemistry of the isoquinoline compounds to optimize NET binding affinity and selectivity. By changing these molecular parameters, the compounds achieve potent NET inhibition (low nanomolar Ki values) while maintaining selectivity against other transporters
2Reliability
If structurally novel 1-[(2'-substituted)-piperazin-1'-yl]-isoquinoline compounds are developed, then high selectivity and potency for NET can be achieved, but the complexity of synthesizing and characterizing these compounds increases
Solution Approach 1:
The patent divides the molecular design into distinct functional segments: the isoquinoline core structure provides the primary binding interaction, while the 2'-substituted piperazine ring provides additional selectivity and pharmacokinetic properties. This segmentation allows for systematic optimization of each segment's contribution to overall NET binding affinity and selectivity
3Measurement precision
If radioactive tracers are used for PET and SPECT imaging, then quantitative detection of NET densities can be achieved, but the need for specialized radiolabeling procedures and facilities increases
Solution Approach 1:
The patent uses radioisotopes (such as fluorine-18 or carbon-11) as intermediaries to label the isoquinoline compounds, enabling non-invasive quantitative imaging of NET distribution and density in the brain. The radiolabeled compounds serve as tracers that maintain the selective binding properties of the parent compounds while providing detectable signals for PET or SPECT imaging
Solution Approach 2:
The patent replaces invasive tissue sampling and post-mortem analysis with non-invasive nuclear medicine imaging techniques. By substituting mechanical/biological sampling methods with radiotracer-based imaging, the patent enables in vivo quantification of NET densities in living subjects, providing a powerful diagnostic tool for CNS disorders
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide effective treatment and diagnostic tools for NET-related disorders by offering high selectivity and potency for NET, reducing interactions with other CNS targets, and enabling quantitative detection and quantification of NET in vivo and in vitro.
Implementation Method 1
radioactive tracer forms of the compounds, which have radioactive atoms bonded to carbon atoms of the compound structures. The tracers are used to quantitatively detect NET and NET distributions using in vivo and in vitro imaging methods
Data Source
AI summary
Racemic mixtures and enantiomerically pure forms of novel 1-[(2′-substituted)-piperazin-1′-yl]-isoquinolines are norepinephrine (NE) transporter (NET) inhibitor compounds. Compounds of the invention are considered therapeutic agents for central nervous system (CNS) diseases and disorders, without limitation, including neurodegeneration, anxiety, depression, attention deficit disorders, drug dependency, and post traumatic stress disorder. Examples of the chemical syntheses of the compounds of the invention are provided. The isoquinoline compounds of the invention competitively bind at NET at nanomolar concentrations. The isoquinoline agents of the invention bind selectively to NET over other competitive transporter targets and receptor binding sites, including those of serotonin and dopamine, amongst others. The chemical syntheses of the invention are suitable for labeling with radionuclide atoms. Radiolabeled forms of the novel 1-[(2′-substituted)-piperazin-1′-yl]-isoquinoline compounds are positron emission tomography and single photon emission tomography imaging tracers. Methods of in vivo imaging with the tracers within various subjects and tissues therein, including regions of the brain, are provided. Imaging methods with the tracers in combination other NET inhibitor agents are provided. The imaging methods within subjects allow quantitative detection of NET, determinations of NET distributions, and measures of tracer interactions at NET in the presence or absence of non-radioactive NET agents. The tracer imaging methods are suitable to locate, diagnose, identify, evaluate, detect or quantitate NET, or abnormalities of NET, or NE abnormalities; that are associated with various CNS diseases and disorders.